The Beauty Health Company
General ticker "SKIN" information:
- Sector: Consumer Staples
- Industry: Household & Personal Products
- Capitalization: $185.7M (TTM average)
The Beauty Health Company does not follow the US Stock Market performance with the rate: -27.1%.
Estimated limits based on current volatility of 4.9%: low 0.65$, high 0.72$
Factors to consider:
- Earnings expected soon, date: 2026-08-06 amc
- Total employees count: 613 (-20.3%) as of 2025
- North and South America accounted for 64.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Reputation and brand risks, Regulatory and compliance, Supply chain disruptions, Intense cost pressure
- Current price 45.9% below estimated low
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.27$, 2.49$]
- 2026-12-31 to 2027-12-31 estimated range: [1.35$, 2.59$]
Financial Metrics affecting the SKIN estimates:
- Positive: with PPE of -7.2 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 20.48 > 12.98
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0.11 <= 0.27
- Positive: 0 < Industry operating cash flow per share per price (median), % of 4.41
- Positive: -3.09 < Return on assets ratio (scaled to [-100,100]) of -1.87
- Positive: Inventory ratio change, % of -2.88 <= -0.76
Short-term SKIN quotes
Long-term SKIN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $397.99MM | $334.29MM | $300.79MM |
| Operating Expenses | $528.91MM | $402.07MM | $321.59MM |
| Operating Income | $-130.92MM | $-67.77MM | $-20.80MM |
| Non-Operating Income | $29.03MM | $38.22MM | $14.87MM |
| Interest Expense | $13.65MM | $10.41MM | $19.33MM |
| R&D Expense | $10.10MM | $6.30MM | $5.63MM |
| Income(Loss) | $-101.89MM | $-29.55MM | $-5.94MM |
| Taxes | $-1.77MM | $-0.45MM | $3.58MM |
| Net Income(Loss)* | $-100.12MM | $-29.10MM | $-9.52MM |
| Stockholders Equity | $59.39MM | $51.80MM | $61.06MM |
| Inventory | $91.32MM | $69.11MM | $48.00MM |
| Assets | $929.11MM | $685.68MM | $499.80MM |
| Operating Cash Flow | $21.75MM | $16.13MM | $37.50MM |
| Capital expenditure | $13.05MM | $6.79MM | $0.30MM |
| Investing Cash Flow | $-31.51MM | $-6.79MM | $-5.16MM |
| Financing Cash Flow | $-37.45MM | $-158.34MM | $-174.90MM |
| Earnings Per Share** | $-0.76 | $-0.23 | $-0.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.